LEMS
MCID: LMB002
MIFTS: 49

Lambert-Eaton Myasthenic Syndrome (LEMS) malady

Categories: Rare diseases, Neuronal diseases

Aliases & Classifications for Lambert-Eaton Myasthenic Syndrome

About this section
Sources:
11Disease Ontology, 13DISEASES, 30ICD10, 31ICD10 via Orphanet, 32ICD9CM, 39MeSH, 40MESH via Orphanet, 45NCIt, 48NIH Rare Diseases, 49NINDS, 50Novoseek, 54Orphanet, 62SNOMED-CT, 68UMLS, 69UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Lambert-Eaton Myasthenic Syndrome:

Name: Lambert-Eaton Myasthenic Syndrome 11 49 54 50 39 13 68
Lems 11 48
Myasthenic-Myopathic Syndrome of Lambert-Eaton 48
Myasthenic Syndrome of Lambert-Eaton 48
Lambert Eaton Myasthenic Syndrome 48
 
Lambert-Eaton Syndrome 11
Eaton Lambert Syndrome 48
Lambert Eaton Syndrome 48
Eaton-Lambert Syndrome 11

Characteristics:

Orphanet epidemiological data:

54
lambert-eaton myasthenic syndrome:
Inheritance: Not applicable; Prevalence: <1/1000000 (Netherlands),1-9/100000 (Europe),1-9/1000000 (Worldwide); Age of onset: Adult; Age of death: normal life expectancy

Classifications:



External Ids:

Disease Ontology11 DOID:0050214
ICD1030 G70.80, G73.1
ICD9CM32 358.3
MeSH39 D015624
NCIt45 C3155
SNOMED-CT62 230688006, 56989000
Orphanet54 ORPHA43393
MESH via Orphanet40 D015624
UMLS via Orphanet69 C0022972
ICD10 via Orphanet31 G73.1

Summaries for Lambert-Eaton Myasthenic Syndrome

About this section
NINDS:49 Lambert-Eaton myasthenic syndrome (LEMS) is a disorder of the neuromuscular junction-the site where nerve cells meet muscle cells and help activate the muscles. It is caused by a disruption of electrical impulses between these nerve and muscle cells. LEMS is an autoimmune condition; in such disorders the immune system, which normally protects the body from foreign organisms, mistakenly attacks the body's own tissues. The disruption of electrical impulses is associated with antibodies produced as a consequence of this autoimmunity. Symptoms include muscle weakness, a tingling sensation in the affected areas, fatigue, and dry mouth. LEMS is closely associated with cancer, in particular small cell lung cancer. More than half the individuals diagnosed with LEMS also develop small cell lung cancer. LEMS may appear up to 3 years before cancer is diagnosed.

MalaCards based summary: Lambert-Eaton Myasthenic Syndrome, also known as LEMS, is related to paraneoplastic syndromes and myasthenic syndrome, congenital, 7, presynaptic. An important gene associated with Lambert-Eaton Myasthenic Syndrome is CACNB2 (Calcium Voltage-Gated Channel Auxiliary Subunit Beta 2), and among its related pathways are Deactivation of the beta-catenin transactivating complex and Nicotine addiction. Affiliated tissues include lung, prostate and t cells, and related mouse phenotypes are Decreased viability and behavior/neurological.

NIH Rare Diseases:48 Lambert eaton myasthenic syndrome (lems) is a disorder of the neuromuscular junction. the neuromuscular junction is the site where nerve cells meet muscle cells and help activate the muscles. this syndrome occurs when antibodies interfere with electrical impulses between the nerve and muscle cells. it may be associated with other autoimmune diseases, or more commonly coincide with or precede a diagnosis of cancer such as small cell lung cancer. symptoms may include muscle weakness, a tingling sensation in the affected areas, fatigue, and dry mouth. treatment of an underlying disorder or cancer is the first priority of treatment. last updated: 12/22/2016

Disease Ontology:11 A neuromuscular junction disease that is characterized by an abnormality of acetylcholine (ACh) release at the neuromuscular junction which results from an autoimmune attack against voltage-gated calcium channels (VGCC) on the presynaptic motor nerve terminal.

Wikipedia:71 Lambert–Eaton myasthenic syndrome (LEMS) is a rare autoimmune disorder that is characterized by... more...

Related Diseases for Lambert-Eaton Myasthenic Syndrome

About this section

Graphical network of the top 20 diseases related to Lambert-Eaton Myasthenic Syndrome:



Diseases related to lambert-eaton myasthenic syndrome

Symptoms & Phenotypes for Lambert-Eaton Myasthenic Syndrome

About this section

GenomeRNAi Phenotypes related to Lambert-Eaton Myasthenic Syndrome according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00381-A-19.7MUSK, SOX2, SYT2, TTN

MGI Mouse Phenotypes related to Lambert-Eaton Myasthenic Syndrome according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053867.8CACNA1A, CACNA1B, MUSK, SOX2, SOX3, SYT2
2MP:00053767.5CACNA1A, CACNA1B, CACNB2, ERC1, MUSK, SOX2
3MP:00053787.5CACNA1A, CACNA1B, CACNB2, MUSK, SOX2, SOX3
4MP:00107687.1CACNA1A, CACNA1B, CACNB2, ERC1, MUSK, SOX2
5MP:00036317.1CACNA1A, CACNA1B, CACNB2, MUSK, SOX2, SOX3

Drugs & Therapeutics for Lambert-Eaton Myasthenic Syndrome

About this section

Drugs for Lambert-Eaton Myasthenic Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 23)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
4-AminopyridineapprovedPhase 3, Phase 269504-24-51727
Synonyms:
.gamma.-Aminopyridine
275875_ALDRICH
36687_FLUKA
36687_RIEDEL
4 AP
4 Aminopyridine
4 Aminopyridine Sustained Release
4-AP
4-Aminopyridine
4-Aminopyridine 10
4-Aminopyridine Sustained Release
4-Pyridinamine
4-Pyridylamine
4-aminopyridine
5-22-09-00106 (Beilstein Handbook Reference)
504-24-5
A 0152
A0414
A78403_ALDRICH
AB1004971
AC-907/25014071
AC1L1C3R
AC1Q52BM
AI3-52547
AKOS000119896
Amaya
Amino-4 pyridine
Amino-4-Pyridine
Ampydin
Ampyra
Avitrol
Avitrol 200
BB_SC-6974
BRN 0105782
BSPBio_001562
Bio1_000353
Bio1_000842
Bio1_001331
Bio2_000282
Bio2_000762
C13728
C5H6N2
CHEBI:34385
CHEMBL284348
CID1727
Caswell No. 038
Compound 1861
D015761
D04127
Dalfampridine
DivK1c_000572
EINECS 207-987-9
EL-970
EPA Pesticide Chemical Code 069201
EU-0100032
FT-0083754
Fampridina
Fampridine
Fampridine (USAN/INN)
Fampridine SR
Fampridine [USAN:INN]
Fampridine-PR
Fampridine-SR
Fampridinum
HC150041
HMS1361O04
HMS1791O04
HMS1921H15
HMS1989O04
HMS2092F05
HMS501M14
HSDB 6037
IDI1_000572
IDI1_034032
InChI=1/C5H6N2/c6-5-1-3-7-4-2-5/h1-4H,(H2,6,7
KBio1_000572
 
KBio2_000282
KBio2_000635
KBio2_002850
KBio2_003203
KBio2_005418
KBio2_005771
KBio3_000563
KBio3_000564
KBio3_001888
KBioGR_000282
KBioGR_001505
KBioSS_000282
KBioSS_000635
LS-130202
Lopac-A-0152
Lopac0_000032
MLS000069400
Mi-W-3
MolPort-000-146-022
N07XX07
NCGC00015009-01
NCGC00015009-03
NCGC00015009-12
NCGC00024890-01
NCGC00024890-02
NCGC00024890-03
NCGC00024890-04
NCGC00024890-05
NCGC00024890-06
NCGC00024890-07
NCGC00024890-08
NCGC00024890-09
NCGC00024890-10
NINDS_000572
NSC 15041
NSC15041
Neurelan
Neurelan (TN)
P-Aminopyridine
PYRIDINE,4-AMINO
Philips 1861
Phillips 1861
Pimadin (free base)
Prc 1237
Pymadin
Pymadine
RCRA waste no. P008
SDCCGMLS-0066228.P001
SMR000058211
SPBio_001486
SPECTRUM1501130
STK298717
Spectrum2_001413
Spectrum3_000914
Spectrum4_001013
Spectrum5_001501
Spectrum_000155
Sustained Release, 4-Aminopyridine
TL8003344
Tocris-0940
UNII-BH3B64OKL9
UPCMLD-DP125
UPCMLD-DP125:001
VMI 10-3
VMI 103
VMI-10-3
VMI-103
VMI103
WLN: T6NJ DZ
[J.Pharmacol.Exp.Ther. 275:864 (1995)]
gamma-Aminopyridine
nchem.892-comp4
p-Aminopyridine
p-Aminopyridine [UN2671] [Poison]
p-Aminopyridine [UN2671] [Poison]
pyridin-4-amine
pyridin-4-ylamine
2Potassium Channel BlockersPhase 3, Phase 2180
33,4-diaminopyridinePhase 3, Phase 220
4
EphedrineapprovedPhase 1, Phase 2628299-42-39294
Synonyms:
( )-Pseudoephedrine
(+)-Ephedrin
(+)-Ephedrine
(+)-Pseudoephedrine
(+)-psi-Ephedrine
(+)-threo-Ephedrine
(+-)-Ephedrine
(-)-Ephedrine
(-)-Pseudoephedrine
(-)-psi-Ephedrine
(-)-threo-Ephedrine
(1R,2R)-Ephedrine
(1R,2S)-1-Phenyl-1-hydroxy-2-methylaminopropane
(1S,2R)-Ephedrine
(L)-EPHEDRINE
--EPHEDRINE
1-EPHEDRINE
1-Sedrin
134910_ALDRICH
287636_ALDRICH
287644_ALDRICH
299-42-3
304-87-0
30987-59-8
321-96-0
321-97-1
321-98-2
37577-31-4
38732-95-5
45261_FLUKA
4607-45-8
50-98-6
50906-05-3
53214-57-6
649031_ALDRICH
6912-63-6
7009-81-6
90-82-4
968-63-8
AC-20231
AC-20292
AC1L1JGK
AC1L1NUA
AC1L1RFA
AC1L1SR1
AC1L1T31
AC1L1Y3M
AC1O8JUO
AC1Q3XJE
AC1Q3XJM
AC1Q3XJN
AC1Q59F5
AC1Q7701
AI3-02761
AKOS000268842
AR-1A0126
AR-1I7143
Acunaso
Acunaso (TN)
Afrinol
Ambap299-42-3
BIDD:GT0817
BRN 3197916
BRN 4231286
BSPBio_001946
BSPBio_001968
BSPBio_003261
Benylin Decongestant
Besan
Biophedrin
C01575
C02765
C10H15NO
CHEBI:15407
CHEBI:51209
CHEMBL1590
CHEMBL211456
CHEMBL357080
CID11972440
CID5032
CID62946
CID6710657
CID7028
CID8650
CID9294
CID9457
CPD-9954
CPDD 0049
Cenafed
D00124
D08449
DB00852
DB01364
Decofed
DivK1c_000181
DivK1c_000451
DivK1c_000461
Drixoral N.D.
EINECS 202-017-0
EINECS 202-018-6
EINECS 206-080-5
EINECS 206-292-8
EINECS 206-293-3
Eciphin
Efedrin
Efidac/24
Eltor 120
Ephedral
Ephedremal
Ephedrin
Ephedrine
Ephedrine (TN)
Ephedrine (USP)
Ephedrine [USAN:BAN]
Ephedrine l-form
Ephedrital
Ephedrol
Ephedrosan
Ephedrotal
Ephedsol
Ephendronal
Ephoxamin
Fedrin
Genaphed
HSDB 3072
HSDB 3177
I-Sedrin
I01-3584
I01-8925
I01-8928
 
IDI1_000181
IDI1_000451
IDI1_000461
Isoephedrine
Jsp005664
KBio1_000181
KBio1_000451
KBio1_000461
KBio2_001358
KBio2_001500
KBio2_003926
KBio2_004068
KBio2_006494
KBio2_006636
KBio3_001188
KBio3_001446
KBio3_002762
KBioGR_001013
KBioGR_001763
KBioSS_001358
KBioSS_001500
KST-1A9168
Kratedyn
L(+)-psi-Ephedrine
L(-)-Ephedrine
L-(+)-Ephedrine
L-(-)-Ephedrine
L-Ephedrine
L-erythro-2-(Methylamino)-1-phenylpropan-1-ol
L000968
LS-125921
LS-125922
LS-43083
LS-63961
LS-63962
LS-63963
LS-63964
Lexofedrin
Lopac-E-3250
Lopac0_000501
MLS000069657
Manadrin
Mandrin
Maxenal
MolPort-001-684-474
MolPort-001-684-477
MolPort-001-684-478
MolPort-001-684-479
MolPort-001-769-085
Myfedrine
NCGC00015408-01
NCGC00015408-02
NCGC00162174-01
NCGC00178180-01
NCGC00178889-01
NCI-C55652
NCI60_002955
NINDS_000181
NINDS_000451
NINDS_000461
NSC 165609
NSC 170951
NSC 8971
NSC165609
NSC170951
NSC8971
Nasol
Neodurasina
Neodurasina (TN)
Oprea1_287330
PDSP1_000168
PDSP1_001106
PDSP1_001343
PDSP1_001345
PDSP1_001346
PDSP1_001347
PDSP2_000167
PDSP2_001090
PDSP2_001327
PDSP2_001329
PDSP2_001330
PDSP2_001331
PSEUDOEPHEDRINE
Pedia Care
Pseudo
Pseudo 60's
Pseudo-12
Pseudoefedrina
Pseudoephedrine (D)
Pseudoephedrinum
Psi-ephedrin
Psi-ephedrine
Robidrine
SMR000059174
SPBio_000214
SPBio_001365
SPBio_001377
ST023802
STK367993
STOCK1N-42675
Sanedrine
Spectrum2_000137
Spectrum2_001303
Spectrum2_001309
Spectrum3_000414
Spectrum3_000563
Spectrum3_001771
Spectrum4_000497
Spectrum4_001162
Spectrum5_000650
Spectrum5_000879
Spectrum5_001106
Spectrum_000878
Spectrum_001020
Sudafed
Sudafed Decongestant
UNII-03VRY66076
UNII-7CUC9DDI9F
UNII-GN83C131XS
Vencipon
WLN: QYR & Y1 & M1
WLN: QYR&Y1&M1
Zephrol
d-Ephedrine
d-Isoephedrine
d-Pseudoephedrine
d-psi-Ephedrine
l-Ephedrine
l-Pseudoephedrine
racephedrine
trans-Ephedrine
5
PseudoephedrineapprovedPhase 1, Phase 262890-82-47028
Synonyms:
( )-Pseudoephedrine
(+) threo-2-(methylamino)-1-phenyl-1-propanol
(+)-(1S,2S)-Pseudoephedrine
(+)-Pseudoephedrine
(+)-psi-Ephedrine
(+)-threo-Ephedrine
(1S,2S)-(+)-Pseudoephedrine
(1S,2S)-2-(methylamino)-1-phenylpropan-1-ol
(1S,2S)-2-Methylamino-1-phenyl-1-propanol
(1S,2S)-Pseudoephedrine
(1S,2S)-Pseudoephedrine, polymer-bound
1-Ephedrine
2-(Methylamino)-1-phenyl-1-propanol
287636_ALDRICH
304-87-0
30987-59-8
37577-31-4
649031_ALDRICH
90-82-4
AC-20292
AC1L1NUA
Acunaso
Acunaso (TN)
Afrinol
BIDD:GT0817
BRD-K84175871-003-02-2
BSPBio_003261
Balminil Decongestant Syrup
Benylin Decongestant
Benzenemethanol, alpha-((1S)-1-(methylamino)ethyl)-, (alpha-S)- (9CI)
Besan
C02765
C10H15NO
CHEBI:51209
CHEMBL1590
CID7028
CPD-9954
Cenafed
D-Isoephedrine
D-Pseudoephedrine
D-Pseudoephedrine base
D-Psi-2-Methylamino-1-phenyl-1-propanol
D-Psi-Ephedrine
D08449
DB00852
Decofed
Dimetapp Decongestant
Dimetapp Decongestant Pediatric Drops
DivK1c_000451
Drixoral N.D.
Drixoral Nasal Decongestant
EINECS 202-018-6
Efidac 24 Pseudoephedrine Hcl
Efidac/24
Eltor 120
Ephedrine
Genaphed
HSDB 3177
I01-8928
IDI1_000451
Isoephedrine
KBio1_000451
 
KBio2_001358
KBio2_003926
KBio2_006494
KBio3_002762
KBioGR_001763
KBioSS_001358
L(+)-Psi-Ephedrine
L(+)-psi-Ephedrine
L-(+)-Pseudoephedrine
LS-125922
Lopac-E-3250
Maxenal
MolPort-001-684-474
Myfedrine
NCGC00015408-01
NCGC00178180-01
NCI60_002955
NINDS_000451
Neodurasina
Neodurasina (TN)
Novafed
PDSP1_001347
PSEUDOEPHEDRINE
Pedia Care
Pseudo
Pseudo 60's
Pseudo-12
Pseudoefedrina
Pseudoefedrina [INN-Spanish]
Pseudoephedrine
Pseudoephedrine (D)
Pseudoephedrine (INN)
Pseudoephedrine D-form
Pseudoephedrine Ephedrine
Pseudoephedrine [INN:BAN]
Pseudoephedrine d-form
Pseudoephedrinum
Pseudoephedrinum [INN-Latin]
Psi-ephedrin
Psi-ephedrine
Robidrine
SPBio_001365
STOCK1N-42675
Spectrum2_001303
Spectrum3_001771
Spectrum4_001162
Spectrum5_000650
Spectrum_000878
Sudafed
Sudafed Decongestant
Sudafed Decongestant 12 Hour
Sudafed Decongestant Extra Strength
Triaminic AM Decongestant Formula
Triaminic Infant Oral Decongestant Drops
UNII-7CUC9DDI9F
alpha-(1-(Methylamino)ethyl)benzyl alcohol
d-Isoephedrine
d-Pseudoephedrine
d-psi-2-Methylamino-1-phenyl-1-propanol
d-psi-Ephedrine
pseudoéphédrine
trans-Ephedrine
ψ-ephedrine
6
BenzocaineapprovedPhase 220161994-09-7, 94-09-72337
Synonyms:
(p-(Ethoxycarbonyl)phenylamine
06952_FLUKA
112909_ALDRICH
112909_SIAL
1333-08-0
23239-88-5
23239-88-5 (hydrochloride)
4 Aminobenzoic Acid Ethyl Ester
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-14-00-01129 (Beilstein Handbook Reference)
4-Aminobenzoate
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Aminobenzoic acid, ethyl ester
4-Carbethoxyaniline
4-amino-benzoic acid ethyl ester
4-aminobenzoic acid ethyl ester
71123-91-6
94-09-7
94-09-7 (Parent)
A0271
AB00051923
AC1L1DGC
AC1Q341A
AC1Q64JE
AE-562/40377256
AI3-02081
AKOS000119763
AR-1H9065
Acetate, Benzocaine
Aethoform
Aethylium paraminobenzoicum
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthesinum
Anaesthin
Anestezin
Anestezin [Russian]
Anesthesin
Anesthesine
Anesthone
BB_SC-0019
BPBio1_001017
BRD-K75466013-001-05-2
BRN 0638434
BSPBio_000923
BSPBio_001908
Baby Anbesol
Bensokain
Benzoak
Benzocaina
Benzocaina [INN-Spanish]
Benzocaine
Benzocaine (USP/INN)
Benzocaine Acetate
Benzocaine Formate
Benzocaine Hydrobromide
Benzocaine Hydrochloride
Benzocaine Methanesulfonate
Benzocaine [INN:BAN]
Benzocainum
Benzocainum [INN-Latin]
Benzoic acid, 4-amino-, ethyl ester
Benzoic acid, 4-amino-, ethyl ester, hydrochloride
Benzoic acid, amino-, ethyl ester
Benzoic acid, p-amino-, ethyl ester
C07527
CAS-94-09-7
CHEBI:116735
CHEMBL278172
CID2337
Caswell No. 430A
Chloraseptic
D001566
D00552
DB01086
Dermoplast
Diet Ayds
DivK1c_000932
E1501_SIGMA
EINECS 202-303-5
EPA Pesticide Chemical Code 097001
ETHYL-P-AMINOBENZOATE
Ethoform
Ethoforme
Ethyl 4-aminobenzoate
Ethyl 4-aminobenzoate hydrochloride
Ethyl 4-aminobenzoic acid
Ethyl Aminobenzoate
Ethyl PABA
 
Ethyl aminobenzoate
Ethyl aminobenzoate (JP15)
Ethyl aminobenzoate (VAN)
Ethyl aminobenzoic acid
Ethyl p-Aminobenzoate
Ethyl p-Aminophenylcarboxylate
Ethyl p-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethylester kyseliny p-aminobenzoove
Ethylester kyseliny p-aminobenzoove [Czech]
Ethylis aminobenzoas
Formate, Benzocaine
HMS1570O05
HMS1920G09
HMS2091M11
HMS502O14
HSDB 7225
Hurricaine
Hydrobromide, Benzocaine
Hydrochloride, Benzocaine
I05-0204
IDI1_000932
Identhesin
KBio1_000932
KBio2_000474
KBio2_003042
KBio2_005610
KBio3_001408
KBioGR_000658
KBioSS_000474
Keloform
LS-35847
MLS001331704
MLS002153970
Methanesulfonate, Benzocaine
MolPort-000-871-526
NCGC00016352-01
NCGC00094598-01
NCGC00094598-02
NINDS_000932
NSC 122792
NSC 41531
NSC41531
NSC4688
Norcain
Norcaine
Norcainum
Oprea1_750694
Oprea1_827402
Ora-jel
Orabase-B
Orthesin
Otocain
Outgro
Parathesin
Parathesin (TN)
Parathesine
Prestwick0_000712
Prestwick1_000712
Prestwick2_000712
Prestwick3_000712
Prestwick_991
SMR000059025
SPBio_000134
SPBio_002844
SPECTRUM1500139
STK043620
Slim Mint Gum
Solarcaine
Solu H
Spectrum2_000117
Spectrum3_000314
Spectrum4_000249
Spectrum5_000860
Spectrum_000074
Topcaine
UNII-U3RSY48JW5
WLN: ZR DVO2
ZINC12358719
benzocaine
ethylaminobenzoate-4
h-4-abz-oet
nchembio.182-comp4
p-(Ethoxycarbonyl)aniline
p-Aminobenzoate
p-Aminobenzoic acid
p-Aminobenzoic acid ethyl ester
p-Aminobenzoic acid, ethyl ester
p-Aminobenzoic ethyl ester
p-Carbethoxyaniline
p-Ethoxycarboxylic Aniline
p-Ethoxycarboxylic aniline
7tannic acidapproved, NutraceuticalPhase 22016
8Neurotransmitter AgentsPhase 1, Phase 218340
9Vasoconstrictor AgentsPhase 1, Phase 22122
10Respiratory System AgentsPhase 1, Phase 24997
11Peripheral Nervous System AgentsPhase 1, Phase 223689
12Nasal DecongestantsPhase 1, Phase 2598
13Central Nervous System StimulantsPhase 1, Phase 22211
14Adrenergic AgentsPhase 1, Phase 25352
15Anti-Asthmatic AgentsPhase 1, Phase 23488
16Bronchodilator AgentsPhase 1, Phase 22965
17Autonomic AgentsPhase 1, Phase 210150
18Tocolytic AgentsPhase 1739
19AlbuterolPhase 1429
20Adrenergic AgonistsPhase 13027
21Adrenergic beta-AgonistsPhase 11714
22Adrenergic beta-2 Receptor AgonistsPhase 1957
23
nivolumabapproved424946414-94-4
Synonyms:
BMS-936558
 
MDX-1106
ONO-4538
nivolumab

Interventional clinical trials:

(show all 22)
idNameStatusNCT IDPhase
1A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)CompletedNCT01377922Phase 3
2Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)RecruitingNCT02970162Phase 3
3Amifampridine Phosphate for the Treatment of Congenital Myasthenic SyndromesRecruitingNCT02562066Phase 3
4Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton SyndromeAvailableNCT01825395Phase 3
5Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic SyndromeUnknown statusNCT01511978Phase 2
6Ephedrine for the Treatment of Congenital MyastheniaUnknown statusNCT00541216Phase 1, Phase 2
7Efficacy of Albuterol in the Treatment of Congenital Myasthenic SyndromesCompletedNCT01203592Phase 1
8Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic SyndromeCompletedNCT00004832
9Pregnancy Outcomes in Congenital Myasthenie SyndromeCompletedNCT01474980
103,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)RecruitingNCT00872950
11Congenital Muscle Disease Study of Patient and Family Reported Medical InformationRecruitingNCT01403402
12National Registry for Egyptian Pediatric Neuromuscular DiseasesRecruitingNCT02124616
13Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology PracticeRecruitingNCT02847728
14Treatment of Lambert-Eaton Syndrome With 3,4 DiaminopyridineAvailableNCT00994916
15Treatment of Lambert-Eaton Syndrome With 3,4 DAPAvailableNCT00704925
163,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)AvailableNCT02012933
17Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia and Lambert-Eaton SyndromeAvailableNCT03062631
18Treatment Use of 3,4-DiaminopyridineAvailableNCT01765140
19Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndrome (CMS), or Downbeat Nystagmus PatientsAvailableNCT02189720
20Controlled Trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS)Enrolling by invitationNCT02090725
21Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic SyndromeNo longer availableNCT01373333
22Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAPNo longer availableNCT01378546

Search NIH Clinical Center for Lambert-Eaton Myasthenic Syndrome


Cochrane evidence based reviews: lambert-eaton myasthenic syndrome

Genetic Tests for Lambert-Eaton Myasthenic Syndrome

About this section

Anatomical Context for Lambert-Eaton Myasthenic Syndrome

About this section

MalaCards organs/tissues related to Lambert-Eaton Myasthenic Syndrome:

36
Lung, Prostate, T cells, B cells, Pituitary, Testes, Breast

Publications for Lambert-Eaton Myasthenic Syndrome

About this section

Articles related to Lambert-Eaton Myasthenic Syndrome:

(show top 50)    (show all 374)
idTitleAuthorsYear
1
Successful treatment of Lambert-Eaton myasthenic syndrome in a small cell lung cancer patient using 3,4-diaminopyridine: A case report. (26998103)
2016
2
Palliative care for a patient with Lambert-Eaton myasthenic syndrome: role of 3,4-diaminopyridine. (27506750)
2016
3
Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome. (27922503)
2016
4
Tubular aggregates in autoimmune Lambert-Eaton myasthenic syndrome. (27816328)
2016
5
Lambert-Eaton myasthenic syndrome (LEMS): Epidemiology and therapeutic response in the national Veterans Affairs (VA) population. (27997683)
2016
6
Modelling the response to low-frequency repetitive nerve stimulation of myasthenia gravis and Lambert-Eaton myasthenic syndrome. (27016366)
2016
7
Relapse of both small cell lung cancer and Lambert-Eaton myasthenic syndrome after a 13-year disease-free survival period. (27370896)
2016
8
Lambert-Eaton myasthenic syndrome in a patient with small-cell lung cancer: A case report. (26622673)
2015
9
Lambert-Eaton Myasthenic Syndrome: Ocular Signs and Symptoms. (25993122)
2015
10
Lambert-Eaton myasthenic syndrome and Merkel cell carcinoma. (26452332)
2015
11
Efficacy of intravenous immunoglobulin for treatment of Lambert-Eaton myasthenic syndrome without anti-presynaptic P/Q-type voltage-gated calcium channel antibodies: a case report. (25444432)
2015
12
Long-term observation of incremental response and antibodies to voltage-gated calcium channels in patients with Lambert-Eaton myasthenic syndrome: two case reports. (25885033)
2015
13
Presynaptic Disorders: Lambert-Eaton Myasthenic Syndrome and Botulism. (26502758)
2015
14
Lambert-Eaton myasthenic syndrome in patients with small cell lung cancer: Report of five cases. (26323934)
2015
15
Mediastinal small cell cancer associated with Lambert-Eaton myasthenic syndrome: A case report. (26170921)
2015
16
Repetitive nerve stimulation and single-fiber electromyography in the evaluation of patients with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome: Review of recent literature. (26109387)
2015
17
Lambert-Eaton myasthenic syndrome associated to Merkel cell carcinoma: report of a case. (25698125)
2015
18
Lambert-Eaton myasthenic syndrome and prostatic adenocarcinoma. (26143177)
2015
19
Lambert-Eaton myasthenic syndrome associated with thymic neuroendocrine carcinoma. (25702627)
2015
20
Conjoint occurrence of GABAB receptor antibodies in Lambert-Eaton myasthenic syndrome with antibodies to the voltage gated calcium channel. (24929678)
2014
21
Italian recommendations for Lambert-Eaton myasthenic syndrome (LEMS) management. (24481713)
2014
22
Proteasome inhibitors for malignancy-related Lambert-Eaton myasthenic syndrome. (24464710)
2014
23
Lambert-Eaton myasthenic syndrome during anesthesia: a report of 37 patients. (25468580)
2014
24
Complete reversal of Lambert-Eaton myasthenic syndrome synaptic impairment by the combined use of a K+ channel blocker and a Ca2+ channel agonist. (25015919)
2014
25
Lung squamous carcinoma with two paraneoplastic syndromes -Dermatomyositis and Lambert-Eaton myasthenic syndrome. (25335449)
2014
26
Post-exercise exhaustion in Lambert-Eaton myasthenic syndrome. (24128793)
2014
27
Limbic encephalitis and Lambert Eaton myasthenic syndrome - An immunological profile of a new syndrome. (24269050)
2014
28
Surgery results in complete cure of Lambert-Eaton myasthenic syndrome in a patient with metastatic Merkel cell carcinoma. (24704152)
2014
29
Lambert-Eaton myasthenic syndrome in a 13-year-old girl with Xp11.22-p11.23 duplication. (24461257)
2014
30
Synaptic Pathophysiology and Treatment of Lambert-Eaton Myasthenic Syndrome. (25195700)
2014
31
Myasthenia gravis and lambert-eaton myasthenic syndrome. (25299290)
2014
32
Synaptotagmin 2 mutations cause an autosomal-dominant form of lambert-eaton myasthenic syndrome and nonprogressive motor neuropathy. (25192047)
2014
33
Lambert-Eaton myasthenic syndrome - Diagnosis, pathogenesis and therapy. (25065299)
2014
34
The exhaustibility of Lambert-Eaton myasthenic syndrome. (24125855)
2014
35
Myasthenis Gravis or Lambert-Eaton Myasthenic Syndrome? (25133625)
2014
36
Clinical presentation and differential diagnosis of Lambert-Eaton myasthenic syndrome. (23545618)
2013
37
Child neurology: diagnosis of Lambert-Eaton myasthenic syndrome in children. (23690300)
2013
38
Myopathic EMG findings and type II muscle fiber atrophy in patients with Lambert-Eaton myasthenic syndrome. (23643575)
2013
39
Antibodies to active zone protein ERC1 in Lambert-Eaton myasthenic syndrome. (23583364)
2013
40
Lambert-Eaton Myasthenic Syndrome presenting with a "dropped head syndrome" and associated with antibodies against N-type calcium channels. (23053834)
2013
41
Paraneoplastic syndromes of the neuromuscular junction: therapeutic options in myasthenia gravis, lambert-eaton myasthenic syndrome, and neuromyotonia. (23263888)
2013
42
Single-fiber EMG and clinical correlation in Lambert-Eaton myasthenic syndrome. (23505075)
2013
43
Pseudomyopathic changes in needle electromyography in lambert-eaton myasthenic syndrome. (23970984)
2013
44
Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging in the investigation of Lambert-Eaton myasthenic syndrome. (24141446)
2013
45
Wilms tumor presenting with Lambert-Eaton myasthenic syndrome. (23612377)
2013
46
Lambert-Eaton myasthenic syndrome in mixed small cell carcinoma and adenocarcinoma of extrapulmonary origin. (23298881)
2013
47
Evaluation of a novel calcium channel agonist for therapeutic potential in Lambert-Eaton myasthenic syndrome. (23785168)
2013
48
Long-Term Follow-Up in Infantile-Onset Lambert-Eaton Myasthenic Syndrome. (24114606)
2013
49
Large granular lymphocytic leukemia associated with Lambert-Eaton Myasthenic Syndrome: A case report. (24371773)
2013
50
Low rate repetitive nerve stimulation in Lambert-Eaton myasthenic syndrome: peculiar characteristics of decremental pattern from a single-centre experience. (23036181)
2013

Variations for Lambert-Eaton Myasthenic Syndrome

About this section

Expression for genes affiliated with Lambert-Eaton Myasthenic Syndrome

About this section
Search GEO for disease gene expression data for Lambert-Eaton Myasthenic Syndrome.

Pathways for genes affiliated with Lambert-Eaton Myasthenic Syndrome

About this section

Pathways related to Lambert-Eaton Myasthenic Syndrome according to GeneCards Suite gene sharing:

(show all 15)
idSuper pathwaysScoreTop Affiliating Genes
19.5SOX2, SOX3
29.0CACNA1A, CACNA1B
39.0CACNA1A, CACNA1B
49.0CACNA1A, CACNA1B
58.7CACNA1A, CACNA1B, CACNB2
6
Show member pathways
8.7CACNA1A, CACNA1B, CACNB2
7
Show member pathways
8.7CACNA1A, CACNA1B, CACNB2
8
Show member pathways
8.7CACNA1A, CACNA1B, CACNB2
98.7CACNA1A, CACNA1B, CACNB2
10
Show member pathways
8.7CACNA1A, CACNA1B, CACNB2
118.7CACNA1A, CACNA1B, CACNB2
128.7CACNA1A, CACNA1B, CACNB2
138.7CACNA1A, CACNA1B, CACNB2
14
Show member pathways
8.4CACNA1A, CACNA1B, CACNB2, SYT2
15
Show member pathways
8.2CACNA1A, CACNA1B, CACNB2, HLA-DQA1

GO Terms for genes affiliated with Lambert-Eaton Myasthenic Syndrome

About this section

Cellular components related to Lambert-Eaton Myasthenic Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1voltage-gated calcium channel complexGO:00058918.7CACNA1A, CACNA1B, CACNB2

Biological processes related to Lambert-Eaton Myasthenic Syndrome according to GeneCards Suite gene sharing:

(show all 13)
idNameGO IDScoreTop Affiliating Genes
1neuromuscular junction developmentGO:000752810.5CACNB2, MUSK
2negative regulation of neuron differentiationGO:004566510.1SOX2, SOX3
3pituitary gland developmentGO:002198310.1SOX2, SOX3
4neurotransmitter secretionGO:000726910.1CACNA1B, SYT2
5calcium ion-regulated exocytosis of neurotransmitterGO:004879110.0CACNA1A, SYT2
6regulation of calcium ion-dependent exocytosisGO:00171589.9CACNA1A, SYT2
7membrane depolarizationGO:00518999.7CACNA1A, CACNA1B
8membrane depolarization during action potentialGO:00860109.7CACNA1A, CACNA1B
9calcium ion transmembrane transportGO:00705889.4CACNA1A, CACNA1B, CACNB2
10calcium ion transportGO:00068169.4CACNA1A, CACNA1B, CACNB2
11chemical synaptic transmissionGO:00072689.4CACNA1A, CACNA1B, CACNB2
12regulation of ion transmembrane transportGO:00347659.1CACNA1A, CACNA1B, CACNB2
13response to painGO:00482659.0CACNA1A, CACNA1B

Molecular functions related to Lambert-Eaton Myasthenic Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1calcium channel activityGO:00052629.2CACNA1A, CACNA1B, CACNB2
2high voltage-gated calcium channel activityGO:00083319.2CACNA1A, CACNA1B, CACNB2
3voltage-gated calcium channel activityGO:00052458.7CACNA1A, CACNA1B, CACNB2

Sources for Lambert-Eaton Myasthenic Syndrome

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet